Lyndra Therapeutics Raises $55 Million in Series B Financing

Lyndra Therapeutics, which is moving toward making daily pills a thing
of the past, today announced it has raised $55 million in Series B
financing, funds it will use for Phase II clinical trials, expansion of
its Phase I pipeline and manufacturing scale-up. All original investors
from the company’s $23 million Series A round, led by Polaris Partners,
resubscribed, and new investors include HOPU Investments, Gilead
Sciences, Invus, the Bill & Melinda Gates Foundation and Orient Life.

“The diversity and caliber of our investors, including those who joined
this round, speaks to the importance of addressing unmet therapeutic
need,” said Amy Schulman, CEO and co-founder of Lyndra Therapeutics. “I
am proud of the speed with which the Lyndra team has moved from
demonstrating feasibility to the clinic, and now we are well positioned
to initiate additional Phase I clinical trials and continue our progress
toward Phase II clinical trials.”

“Lyndra’s groundbreaking development in an oral drug delivery system is
very exciting and offers real promise to patients and the healthcare
system. We are delighted to be Lyndra’s partner,” said Cliff Chau,
Partner at HOPU Investments.

Lyndra is moving toward submitting an Investigational New Drug
Application (IND) for a long-acting schizophrenia pill in 2019 in
anticipation of starting a Phase II clinical trial in 2020. It also
plans to bring other drug candidates, including its own therapies and
drugs commercialized with partners, through Phase I, II and III clinical
trials.

“Lyndra’s long-acting therapies have the potential to address a
diversity of disease states,” said Robert Langer, co-founder and Board
Member of Lyndra Therapeutics. “The ability to move from daily to weekly
administration of an oral drug is groundbreaking. I believe Lyndra’s
long-acting oral pill will be truly transformative.”

“Lyndra’s vision is to address unmet need for conditions that affect
large patient populations, starting with schizophrenia, and this funding
moves the company a step closer to late-stage clinical trials and
manufacturing scale-up that will bring this vision to life,” said
Catherine B. Reynolds, Chair of the Board of Directors for Lyndra
Therapeutics.

The announcement comes on the heels of positive
early clinical study results and a Notice
of Allowance from the U.S. Patent and Trademark Office (USPTO) for
intellectual property related to Lyndra’s ultra-long-acting oral dosage
form. To date the dosage form has been safely administered in 50
subjects during Phase I clinical trials in Australia.

About Lyndra Therapeutics’ Platform

Lyndra Therapeutics’ orally administered dosage form is designed to
deliver sustained, steady-state release of one or more drugs for up to a
week or longer while temporarily residing in the stomach. Taking a
single, long-acting pill weekly instead of daily or more often can
improve medication adherence and health outcomes while reducing burdens
on individuals and their caregivers. Inside a familiar capsule is a
star-shaped formulation with active pharmaceutical ingredients that are
released consistently over time. The formulation, which is designed to
open once inside the stomach, eventually exits safely via the
gastrointestinal tract, like undigested food.

About Lyndra Therapeutics

Lyndra Therapeutics aims to improve healthcare outcomes through oral,
ultra-long-acting, sustained-release therapies that change how people
take medicines. Instead of taking medications daily or more frequently,
doses would be administered weekly or monthly, improving medication
adherence for better health outcomes and lower healthcare costs.
Delivering controlled amounts of medicine would also reduce side effects
and improve drug efficacy. For more information, visit the company’s
website www.lyndra.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190129005478/en/